Search

everythinglearnresearchcommunity

for

Search:↓

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.

Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.

Combining 0.5 mg oral finasteride with topical finasteride and minoxidil during an Enclomiphene cycle may help manage increased DHT levels. Monitoring for side effects is advised.

Clascoterone powder is now available, but it's expensive and not widely discussed due to past ineffective results at higher concentrations. Users are skeptical about its effectiveness and are seeking reliable sources.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

User got a hair system after hair transplant and finasteride didn't meet their needs. Hair system cost $200, initial install $150, and user is satisfied with the results.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

3aHSD enzyme's role in hair loss and a crowdfund for research. Goal: explore new treatments, study RU58841, and develop natural topical product.

A new treatment, clascoterone 5% solution, shows significant improvement in male hair loss but is considered expensive and only slightly effective by some. It has no side effects and may influence market competition.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

The user has been using finasteride for two years without results and recently started a new routine involving derma stamping, retinol, and minoxidil, which seems to show progress. The user microneedles about half the week and uses L’Oréal night serum for retinol.

The user experienced noticeable hairline regrowth after starting finasteride for crown hair loss, despite scalp irritation from topical minoxidil. They are impatient for crown results.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The user is using oral finasteride, topical minoxidil, and microneedling for hair loss. Progress has slowed, with the crown showing little change, but the hairline is improving with more thin baby hairs.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

The user shared progress pictures showing hair regrowth after 9 months using 1mg oral finasteride, topical Minoxidil, and Stemoxydine. They experienced a recent shedding at the hairline but are seeing new hair growth.

The conclusion of the conversation is that the user, Michael_Scott1234, has been using topical minoxidil for a long time and recently started using oral finasteride and dermarolling. They have not experienced any side effects from finasteride and are happy with their progress.

The user has been using finasteride for over four years with minimal side effects, successfully stopping hair thinning and achieving some regrowth. They shared progress photos, but some commenters requested clearer pictures of the crown to better assess the treatment's effectiveness.

The conversation is about a new acne treatment cream called Clascoterone Cream 1%, which is the first new mechanism of action for acne in nearly 40 years. One person joked about hoping their face will be as clean as their bald head after using the cream.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.

The user is using oral minoxidil for hair loss and is considering trying Latisse on their hairline. They are also curious about the effects of latanoprost, caffeine, and melatonin topicals.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

Clascoterone, an acne treatment that blocks DHT, is being developed for scalp use against hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

The user is experiencing hair regrowth using finasteride, minoxidil, and KX-826. They regret not starting treatment earlier but are now seeing progress.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.